Clinical trials: Pharmacogenomics
Depression, Anxiety
Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy
A randomized controlled trial comparing pharmacogenomic guided versus standard pharmacist care to optimize antidepressant drug therapy.
- Conditions
- Depression, Anxiety, Major Depressive Disorder, Generalized Anxiety Disorder
- Trial name
- NCT03591224
- Testing
- Pharmacogenomic Testing, Pharmacist Standard of Care
- Where
- 2 sites in Canada
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- John Papastergiou Pharmacy Ltd
Type 2 Diabetes
Pharmacogenomics of Thiazolidinediones
The purpose of this study is to determine predictors of response to pioglitazone, an anti-diabetic medication. The investigators know from randomized clinical trials that some 30% of patients do not respond to this type of…
- Trial name
- PPAR (NCT01135394)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Hematopoietic Cell Transplantation, Oncology
Pharmacogenomic-Guided Supportive Care in Hematopoietic Cell Transplantation
Hematopoietic cell transplantation (HCT) is the only curative treatment modality for many hematologic malignancies. Morbidity and mortality rates have declined drastically over the years, secondary to improvements in both…
- Trial name
- IMPPACT (NCT04727827)
- Testing
- Pharmacogenomic-guided supportive care
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Pain
Pharmacokinetics of Oral Morphine and Pharmacogenomics of CYP2D6 and UGT2B7, in an Urban Pediatric Population Presenting for Elective Surgery
The purpose of this study is to identify and collect samples from children who have taken a single oral dose of the pain medication morphine, and to determine the genetic differences in the way children metabolize (break down in…
- Trial name
- NCT01071499
- Testing
- Morphine
- Where
- Canada
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Depression, Adverse Reaction to Drug
Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients
The purpose of this study is to determine whether pharmacogenomic study predict antidepressant responsiveness in advance before the appearance of the drug effects until 4~6 weeks after drug administration.
- Trial name
- NCT00817375
- Testing
- SSRI treated group, non-SSRI treated group
- Where
- South Korea
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Fungal Infection, Haematological Malignancy
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial
This project aims to address invasive fungal infections in patients, by precision dosing of voriconazole based on CYP2C19 genotype testing with Bayesian dose-forecasting dosing software to develop patient-centric and maximally…
- Conditions
- Fungal Infection, Haematological Malignancy, Blood Cancer, Infectious Disease
- Trial name
- PRAGMATIC (NCT06510699)
- Testing
- genotype-directed dosing with dosing software based on therapeutic drug monitoring
- Where
- 7 sites in United States, Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- The University of Queensland
Healthy Volunteers, Aerosol Therapy
Inhaled Dose Analysis Using a Breath Actuated Nebulizer in Healthy Subjects
The goal of this crossover study is to compare urine drug concentrations using a continuous vibrating mesh nebulizer versus a breath-actuated vibrating mesh nebulizer in healthy volunteers.
- Conditions
- Healthy Volunteers, Aerosol Therapy, Inhaled Drug Dose, Pharmacogenomic Drug Interaction
- Trial name
- NCT06157515
- Testing
- Breath-actuated vibrating mesh nebulizer, Continuous vibrating mesh nebulizer
- Where
- Taiwan
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Chang Gung University
Pharmacogenomics
Effectiveness of an Arabic CPIC-Based Pharmacogenomics Microlearning Program on Community Pharmacists' Clinical Decision-Making in Jordan
Pharmacogenomics (PGx) presents a vital opportunity to optimize medication safety, yet community pharmacists often lack the applied clinical training required to interpret and act upon genetic data.
- Trial name
- NCT07735572
- Testing
- immediate post-intervention clinical decision-making score
- Where
- Jordan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Petra
Pharmacogenetic Testing
Pharmacogenetic Testing in Primary Care
The purpose of this study is to further integrate pharmacogenetic (PGx) testing into clinical practice by educating physicians about pharmacogenetics and offering testing to their patients.
- Trial name
- NCT01600846
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Duke University
Healthy
Genetic Response to Warfarin in Healthy Subjects
The purpose of this study is to determine the importance of genetic differences on individuals' response to warfarin in a group of healthy subjects.
- Trial name
- NCT01520402
- Testing
- Warfarin
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Healthy
Efficacy of Personal Pharmacogenomic Testing as an Educational Tool in the Pharmacy Curriculum
The purpose of this study is to evaluate the use of personal genomic educational testing (PGET) on student knowledge and clinical skills surrounding pharmacogenomic testing to ensure it is of educational benefit to our student…
- Trial name
- NCT04889014
- Testing
- Personal genomic educational testing (PGET), No personal genomic educational testing (NPGET)
- Volunteers
- 233 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Pharmacogenomic Drug Interaction
Trial of Precision Medicine in Emergency Departments
The objectives of this study are to (1) test the feasibility of the clinical implementation of preemptive pharmacogenetic (PGx) testing in the emergency department (ED) and (2) determine if PGx testing (with appropriate decision…
- Trial name
- TOPMEDs (NCT06448091)
- Testing
- Panel-based pharmacogenetic genotyping
- Where
- 3 sites in United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- University of Florida
Pharmacogenomics
Effect of Genetic Polymorphisms of UGT on the PKs of Indapamide in Egyptians
The aim of this works is to investigate the effect of genetic variation of UGT2B7 on human response to treatment with indapamide and its correlation with pharmacokinetic parameters in Egyptian subjects.
- Trial name
- UGT/PKs (NCT05294484)
- Testing
- Indapamide 1.5 MG SR
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
HIV
Genetics and HIV-1 Protease Inhibitors
This study evaluated the blood levels of atazanavir according to a genetic makeup for CYP3A5 (cytochrome P450 3A5, an enzyme that metabolizes atazanavir).
- Trial name
- NCT01388543
- Testing
- Atazanavir
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis
HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness
Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), are rare but life-threatening complications that…
- Conditions
- Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis, Gout and Hyperuricemia
- Trial name
- HLA-SCREEN (NCT07369622)
- Testing
- HLA-B*58:01 Genotyping, Allopurinol Tablet, Febuxostat
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Haiphong University of Medicine and Pharmacy
Diabetes Mellitus, Type 2
Genetics of Response to Canagliflozin
Five daily doses of canagliflozin (300 mg) will be administered to healthy volunteers. Pharmacodynamic responses to canagliflozin will be assessed both at 2 days and 6 days after administration of the first dose of canagliflozin.
- Trial name
- NCT02891954
- Testing
- Canagliflozin
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Healthy Subjects
THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC
This will be an open-label, parallel group, multiple dose study in approximately 48 healthy male or female subjects of African American and Caucasian self-reported race, to assess the effect of CYP3A5 genotype on the PK of MVC…
- Trial name
- NCT02625207
- Testing
- Maraviroc (Part 1), Maraviroc (Part 2), Darunavir/cobicistat (Part 2)
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Individuals With a Disease of Cardiovascular System
Pharmacogenomics of Antithrombotic Drugs -a Register Linkage Study With National Registries and Biobanks in Finland
This is a retrospective cohort study linking data from Finnish Biobanks (Helsinki Biobank, Auria Biobank and THL Biobank), laboratory databases, and national registries of Social Insurance Institution of Finland (Kela) and the…
- Trial name
- NCT04001166
- Testing
- Non-interventional study
- Where
- Finland
- Volunteers
- 7,005 people, healthy volunteers welcome
- Sponsor
- VTT Technical Research Centre of Finland
Pharmacogenomic Testing
VICE-MPRINT: Maternal and Pediatric Pharmacogenetics Survey
The field of pharmacogenetics has progressed from the discovery of genetic variants that cause variable function of drug metabolism enzymes to a cornerstone of clinical precision medicine.
- Trial name
- MPRINT (NCT05037305)
- Testing
- Educational video
- Where
- 2 sites in United States
- Volunteers
- 798 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Novel Oral Anticoagulants, NOACs
Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants
It is general that there are many factors for individual differences of drugs in clinical application, of which genetic factors accounted for more than 20%.
- Conditions
- Novel Oral Anticoagulants, NOACs, Rivaroxaban, Apixaban
- Trial name
- NCT03161496
- Testing
- detection of genotype
- Where
- 17 sites in China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Cui Yimin